Invizius is a clinical stage biotech developing second generation complement therapies to treat inflammatory, fibrotic and autoimmune disorders

Our proprietary technology harnesses and supercharges natural complement regulators to maximise potential patient safety and clinical efficacy

Our lead product, H-Guard, is in clinical development and aims to address serious unmet needs for patients on dialysis and other extracorporeal circuit therapies